https://www.fordham.edu/school-of-law/faculty/directory/full-time/doni-bloomfield

# Doni Bloomfield

![Fordham Law Faculty Doni Bloomfield](/media/home/schools/school-of-law/Bloomfield-480px.jpg)


## Associate Professor of Law

[Curriculum Vitae](https://drive.google.com/file/d/1y-cUqtTwd543E8A5p_FGU0I-I2YPtIQx/view?usp=sharing)[SSRN](https://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=2917097)[[email protected]](/cdn-cgi/l/email-protection#375358595e19555b58585a515e525b5377515845535f565a19525342)

Faculty Assistant

Diane Pinero [[email protected]](/cdn-cgi/l/email-protection#590930373c2b36193f362b3d313834773c3d2c)

### Areas of Expertise

Intellectual Property, Artificial Intelligence, Biosecurity, Antitrust, Export Controls, Law and Economics, Health Law

-
Doni Bloomfield is an Associate Professor of Law at Fordham Law School. He teaches and writes in the areas of intellectual property, biosecurity, antitrust, national security law, torts, and health law. His research examines the role the law plays in encouraging technological progress while reducing risk, both to health and economic well-being.

His recent scholarship has analyzed the application of export controls to intellectual property, the relationship between market competition and supply resilience, and the intersection of FDA and patent law. His work has been published, or is forthcoming, in Science, Washington University Law Review, Iowa Law Review, Antitrust Law Review, BMJ, JAMA, the Journal of Law, Medicine, & Ethics, JAMA Internal Medicine, and elsewhere. He is a Greenwall Faculty Scholar and a fellow at the Thurman Arnold Project at Yale.

Prior to joining Fordham in 2024, Bloomfield was a Senior Research Associate at Johns Hopkins Bloomberg School of Public Health’s Center for Health Security and a postdoctoral fellow at the Program on Regulation, Therapeutics, and Law at Harvard Medical School. He served as a law clerk to Judge Timothy B. Dyk of the Federal Circuit and Judge Patricia A. Millett of the D.C. Circuit.

Bloomfield holds a J.D. from Yale Law School and a B.A. in economic history from the University of Chicago. Before law school, Bloomfield was a biotechnology reporter for Bloomberg News in Boston.


-
### Representative Publications

, 111 Iowa L. Rev. (forthcoming 2026)*Intellectual Antiproperty: Export Controls and the Transformation of IP*, 103 Wash. U. L. Rev. (forthcoming 2026) (with Jeff Gordon)[The Law and Economics of Resilience](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5152700), 21 PLOS Comp. Bio. e1012975 (2025) (with Jaspreet Pannu, Alex Zhu, Robert MacKnight, Moritz Hanke, Gabe Gomes, Anita Cicero, and Thomas Inglesby)*Dual-Use Capabilities of Concern of Biological AI Models*, 52 J. L. Med. & Ethics 439 (2024) (with Aaron S. Kesselheim)*Patent Claim Scope and Biosimilar Competition in the US and EU*, 385 Science 831 (2024) (with Jaspreet Pannu, Alex W. Zhu, Madelena Y. Ng, Ashley Lewis, Eran Bendavid, Steven M. Asch, Tina Hernandez-Boussard, Anita Cicero, and Tom Inglesby) (lead author)*AI and Biosecurity: The Need for Governance*, 86 Antitrust Law Journal 63[Competition and Risk](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3566661)(2024), 377 BMJ E1 (2022) (with Zhigang Liu and Aaron S. Kesselheim) (lead author)*Improving the Quality of Drug Patents with International Awareness*, 182 JAMA Internal Med. 245 (2022) (with Bryan S. Walsh and Aaron S. Kesselheim) (lead author)*Extending Drug Monopolies by Patenting Safe Drug Use*, 8*Characteristics of Clinical Trials Evaluating Biosimilars Treating Cancer: Systematic Review and Meta-Analysis*JAMA Oncology 537 (2022) (with Elvira D’Andrea, Sarosh Nagar, and Aaron S. Kesselheim) (lead author), 41 Health Affairs 787 (2022) (with William B. Feldman, Reed F. Beall, and Aaron S. Kesselheim)*Patents and Exclusivities on Inhalers for Asthma and COPD, 1986-2020*, 40 Nature Biotechnology 1319 (2022) (with William B. Feldman, Reed F. Beall, and Aaron S. Kesselheim)*Brand-name Market Exclusivity for Nebulizer Therapy to Treat Asthma and COPD*, 326 JAMA 1371 (2021) (with Bryan S. Walsh and Aaron S. Kesselheim)*A Court Decision on “Skinny Labeling”: Another Challenge for Less Expensive Drugs*